Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CETP | P11597 | 4/20 | 0.54 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22402591 | 0.87 | TSHR (0.70) | TSHRCETPFOLH1ALDH1A1SRC | |
| SCHEMBL9621949 | 0.84 | TSHR (0.66) | TSHRCETPFOLH1ALDH1A1SRC | |
| SCHEMBL22402661 | 0.82 | TSHR (0.63) | TSHRCETPFOLH1ALDH1A1SRC | |
| SCHEMBL26361306 | 0.81 | TSHR (0.61) | TSHRCETPFOLH1ALDH1A1SRC | |
| SCHEMBL752361 | 0.78 | TSHR (0.68) | TSHRCETPCFTRFOLH1ALDH1A1 | |
| SCHEMBL6135587 | 0.78 | TSHR (0.68) | TSHRCETPFOLH1ALDH1A1SRC | |
| SCHEMBL7631529 | 0.78 | TSHR (0.68) | TSHRCETPFOLH1ALDH1A1SRC | |
| SCHEMBL5400948 | 0.77 | TSHR (0.61) | TSHRCETPCFTRALDH1A1SRC | |
| SCHEMBL17537488 | 0.77 | CFTR (0.73) | TSHRCFTRALDH1A1ALPG | |
| SCHEMBL17488976 | 0.77 | CFTR (0.73) | TSHRCFTRALDH1A1ALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034714-A1 | METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND | EKIMOTO HISAO | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034714-A1 | METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND | NR3C2, NR3C1, MC5R | TSHR 1365/4885CETP 4844/4885CFTR 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.